Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04011683
Other study ID # H-18034040_part2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 1, 2018
Est. completion date December 20, 2021

Study information

Verified date January 2022
Source Steno Diabetes Center Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators hypothesise that patients with type 1 diabetes have clinically relevant, but often unrecognised, episodes of arrhythmias linked to episodes of hypoglycaemia and/or clinically significant fluctuations in plasma glucose.


Description:

30 patients with type 1 diabetes will be recruited for a one-year observational study employing CGM (Continuous glucose monitor) and ILR (Implantable loop recorder). Patients will be scheduled for a three-week run-in period to ensure that the implanted ILR provides reliable data. Patient visits are planned for 0, 3, 6, 9, and 12 months and will include clinical examination, blood and urine samples, echocardiography (only first and last visit) and implant/explant of CGM. After 12 months, the participants will continue with an extended observation period of 2 years employing ILR and clinical examination. Device: Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA) Implantation of a loop-recorder Device: Continuous glucose monitoring (Eversense XL, Senseonics, USA) Monitoring with a continuous glucose monitor


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 20, 2021
Est. primary completion date December 20, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Informed and written consent - Type 1 diabetes diagnosed according to the criteria of the World Health Organization (WHO) - Age 18-80 years - Fulfilling at least one of the below criteria*: 1. Recurrent hypoglycaemia (defined as >1 episode/week with a plasma glucose measurement =3.9 mmol/l within the last 4 weeks) 2. An episode of severe hypoglycaemia within the last year (according to the ADA definition, an event requiring assistance of another person to actively administer carbohydrates and/or glucagon, or take other corrective actions) 3. Hypoglycaemic symptom unawareness (history of impaired autonomic response during hypoglycaemia) (*The aim is that all patients will fulfil criteria a or b. If the targeted sample size cannot be recruited, patients fulfilling criteria c will be included) - Insulin treatment - One or more clinical relevant complications to diabetes defined as**: 1. Nephropathy (creatinine >130 µmol/l and/or microalbuminuria) 2. Macrovascular disease defined as coronary disease (stable angina pectoris. previous unstable angina pectoris or myocardial infarction), cerebrovascular disease (previous stroke or transitional cerebral ischaemia), and peripheral vascular disease (previous intermittent claudication or prior acute ischemia) 3. Peripheral neuropathy with vibration perception threshold of >25 volt determined by biothesiometry 4. Moderate to severe retinopathy - Well-functioning ILR during run-in period (acceptable readings judged by an arrhythmologist) - Participation in the extended study (**The aim is that all patients will fulfil criteria a or b. If the targeted sample size cannot be recruited, patients fulfilling criteria c or d will be included) Exclusion Criteria: - Arrhythmia diagnosed prior to the screening visit - ICD or pacemaker at the time of inclusion - Severe heart failure (left ventricular ejection fraction <25%) - Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease) - Thyroid dysfunction (except for well-regulated eltroxine substituted myxoedema)

Study Design


Locations

Country Name City State
Denmark Clinical Metabolic Physiology, SDCC Copenhagen

Sponsors (4)

Lead Sponsor Collaborator
Steno Diabetes Center Copenhagen Hillerod Hospital, Denmark, University Hospital, Gentofte, Copenhagen, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of cardiac arrhythmias during hypoglycaemia, euglycaemia, hyperglycaemia. Incidence of clinically relevant arrhythmias during hypoglycaemia (plasma glucose =3.9 mmol/l) compared to euglycaemia and hyperglycaemia. Within 12 months
Secondary Prevalence of cardiac arrhythmias Prevalence of clinically relevant arrhythmias Within 12 months
Secondary Cardiac arrhythmias during LGV, HGV. Clinical relevant arrhythmias during low glucose variability (LGV), defined as variations in plasma glucose below or equal to 5 mmol/l within two hours preceding an arrhythmic event, compared to high glucose variability (HGV), defined as variations in plasma glucose above 5 mmol/l within two hours preceding an arrhythmic event. Within 12 months
Secondary The relationship between cardiovascular disease at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV The relationship between cardiovascular disease (heart failure and ischaemic heart disease) at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV Within 12 months
Secondary The relationship between pharmacological treatment at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV The relationship between pharmacological treatment at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV Within 12 months
Secondary The relationship between diabetes complication status at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV The relationship between diabetes complication status (neuropathy, nephropathy, retinopathy) at baseline and clinically relevant arrhythmias in relation to hypoglycaemia and HGV Within 12 months
Secondary Hypoglycaemia and cardiac arrhythmia The correlation between prevalence and total duration of hypoglycaemia and risk of clinically relevant arrhythmias Within 12 months
Secondary Plasma glucose variation and cardiac arrhythmias The correlation between plasma glucose variation (variation in plasma glucose (? mmol/l) within two hours of the event) and risk of clinically relevant arrhythmias Within 12 months
Secondary CV, SD, ADRR, LBGI, HBGI, CONGA-1 and cardiac arrhythmias The correlation between measures of glycaemic variability (coefficient of variation (CV), standard deviation (SD), average daily risk range (ADRR), low blood glucose index (LBGI), high blood glucose index (HBGI) and continuous overlapping net glycaemic action (CONGA-1)) and risk of clinically relevant arrhythmias Within 12 months
Secondary Mean amplitude of glycaemic excursions (MAGE) and cardiac arrhythmia. Difference in mean amplitude of glycaemic excursions (MAGE) two hours preceding an arrhythmic event versus MAGE during non-event Within 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany